

Supplementary Material for manuscript # JASN-2015-04-0369

Supplementary Table I. Patients status at renal replacement therapy initiation.

Patients experiencing a more than 50% reduction in renal function during the study were censored for the primary endpoint; follow-up continued until dialysis onset


	All (N=41)	KD (n=11)	LPD (n=30)	p*
Reason for dialysis initiation (%)				0.71
Severe overhydration	20	28	17	
Hyperkalemia	5	9	3	
Poor appetite, low energy intake, risk for malnutrition	51	45	53	
Poor appetite, severe acidosis	24	18	27	
eGFR (mL/min)	6.5 (6.2-7.1)	6.2 (4.8-7.3)	6.7 (6.3-7.2)	0.02
Proteinuria (g/day)	0.38 (0.31-0.48)	0.32 (0.15-0.64)	0.38 (0.31-0.54)	0.52
BMI (Kg/m ²)	23.1 (22.4-23.8)	23.7 (22.2-25.2)	22.9 (22.1-23.7)	0.31
SGA A (%)	71	64	73	0.54
Mean arterial blood pressure (mmHg)	95.3 (91.4-99.2)	92.8 (85.3-100.3)	96.2 (91.4-101.1)	0.44
Serum urea (mg/dL)	264.7 (247.1-282.2)	212.4 (179.7-245.1)	283.8 (267.1-300.6)	<0.01
Serum uric acid (mg/dL)	6.1 (5.9-6.4)	5.7 (5.4-6.1)	6.3 (6.0-6.6)	0.04
Serum bicarbonate (mEq/L)	14.1 (13.4-14.8)	15.1 (13.5-16.8)	13.8 (12.9-14.6)	0.1
Serum calcium (mg/dL)	3.5 (3.3-3.9)	4.2 (4.2-4.8)	3.3 (3.2-3.5)	<0.01
Serum phosphates (mg/dL)	7.6 (7.0-8.2)	5.5 (4.8-6.1)	8.3 (7.8-8.9)	<0.01
C-reactive Protein (mg/L)	8.1 (7.1-9.2)	10 (8.2-11.8)	7.5 (6.2-8.8)	0.03
Serum albumin (g/dL)	4.0 (4.0-4.1)	3.9 (3.9-4.0)	4.1 (4.0-4.2)	0.17
Serum potassium (mEq/L)	5.2 (5.1-5.4)	5.0 (4.7-5.4)	5.3 (5.1-5.5)	0.17
Data showed as mean or median and 95% Confidence Interval.				
KD - Keto-diet; LPD - low protein diet; eGFR - estimated glomerular filtration rate.				
*KD vs. LPD.				
To convert eGFR in mL/min to mL/s, multiply by 0.01667 – serum urea in mg/dL to mmol/L, multiply by 0.357 – BUN in mg/dL, multiply serum urea by 0.467 – serum bicarbonate in mEq/L to mmol/L, multiply by 1 – serum calcium in mg/dL to mmol/L, multiply by 0.2495 – serum phosphates in mg/dL to mmol/L, multiply by 0.3229 – serum albumin in g/dL to g/L, multiply by 10.				

Supplementary Table II. Reported content of the Ketoacid supplement used in the study (Ketosteril® - Fresenius Kabi, Bad Homburg, Germany)


Component No.	Component Name	mg/pill
1	Ca (RS)-3methyl-2-oxovaleric acid (ketoisoleucine)	67
2	Ca 4-methyl-2-oxovaleric acid (ketoleucine)	101
3	Ca 2-oxo-3-phenylpropionic acid (ketophenylalanine)	68
4	Ca 3-methyl-2-oxobutyric acid (ketovaline)	86
5	Ca (RS)-2-hydroxy-4-methylthio-butyric acid (hydroxymethionine)	59
6	L-Lysine acetate	105
7	L-Threonine	53
8	L-Tryptophan	23
9	L-Histidine	38
10	L-Tyrosine	30
11	Ca	50

Ca, calcium; RS, racemic mixture of both R and S stereoisomers.


Supplementary Figure 1. Proteinuria (g/day) during the study. There was no statistical significant difference between the two groups




Supplementary Figure 2. Mean arterial pressure (mmHg) during the study. There was no statistical significant difference between the two groups




Supplementary Figure 3. Serum urea (mg/dL) during the study. “Δ” implies statistical significant difference between the two groups




Supplementary Figure 4. Serum uric acid (mg/dL) during the study. “Δ” implies statistical significant difference between the two groups



Supplementary Figure 5. C-reactive protein (mg/L) during the study. “Δ” implies statistical significant difference between the two groups



Supplementary Figure 6. Serum albumin (g/dL) during the study. There was no statistical significant difference between the two groups



Supplementary Figure 7. Serum potassium (mEq/L) during the study. “Δ” implies statistical significant difference between the two groups

